Evidence map›Paper›PMID 36545912›Full record

ArticleNeurodegenerative disease management2023

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.

Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert

Open access · hybridAbstract readCommentPatient Education Handout
PubMed Publisher
In one paragraph

Article in Neurodegenerative disease management, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 8 countries.

Klaus SchmiererThe Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-9293-8893
Heinz WiendlDepartment of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.
Celia Oreja-GuevaraDepartment of Neurology, IdISSC, Hospital Universitario Clinico San Carlos, Madrid, Spain.
Diego CentonzeLaboratory of Synaptic Immunopathology, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Anita ChudeckaClinical Research Services, Cytel Inc., Geneva, Switzerland.
Sanjeev RoyGlobal Medical Affairs, Ares Trading S.A., Eysins, Switzerland (an affiliate of Merck KGaA).
Ursula BoschertNeurology & Immunology, Ares Trading S.A., Eysins, Switzerland (an affiliate of Merck KGaA).
Cytel (United States) · USGlobal Affairs Canada · CAMerck Serono (Switzerland) · CHQueen Mary University of London · GBUniversidad Complutense de Madrid · ESUniversity of Münster · DEUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WHAT IS THIS SUMMARY ABOUT?: This is a summary of an article originally published in the WHAT HAPPENED IN THE MAGNIFY-MS STUDY?: A study called MAGNIFY-MS investigated how long it takes for cladribine tablets to begin to work in people with a type of MS called highly active relapsing MS. During the study, some participants received their usual vaccinations against flu (influenza) and against the chickenpox virus (also called varicella zoster virus) as part of their routine medical care. The MAGNIFY-MS study gave the researchers an opportunity to look at how cladribine tablets affect the way the flu and chickenpox virus vaccines work in the body. WHAT WERE THE RESULTS?: Cladribine tablets do not affect how well the body responds to flu and chickenpox vaccines. WHAT DO THE RESULTS MEAN?: PwMS taking cladribine tablets who are vaccinated against chickenpox, flu or both can be protected against these diseases.

Indexed as

ChickenpoxInfluenza, HumanInfluenza VaccinesMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingCladribineHerpesvirus 3, HumanHumansImmunosuppressive AgentsTabletsCladribineImmunosuppressive AgentsInfluenza VaccinesTabletschickenpox vaccinecladribine tabletsflu vaccinelay summarymultiple sclerosisplain language summary

Identifiers

PMID36545912
OpenAlexW4312095161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.